High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort
Neuro-Oncology · 2026
DOI: 10.1093/neuonc/noag145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Shuodan Zhang und 59 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, U.S. Department of Health and Human Services, National Institutes of Health.
Abstract (Originalsprache)
Background
High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well understood. Prognostic factors of clinical outcomes are not well established.
Methods
Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of ≥0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods.
Results
The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival was 88 months. Older age (P = .01) and the presence of an ATRX alteration (P = .04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (P = .01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome.
Conclusions
This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Pathology, The University of Chicago, Chicago, Illinois, USA.
- Department of Pathology, University of California San Diego, San Diego, California, USA.
ORCID-Profile: Shuodan Zhang, Omkar Singh, Karen Dazelle, Martha Quezado, Patrick J Cimino, Zied Abdullaev, Jing Wu, Calixto-Hope Lucas, Karisa C Schreck, Matthias Holdhoff, Peter Pytel, Vanessa Goodwill, Rob Macaulay, William McDonald, Roberta Seidman, Matthew Wood, Krishna Bharani, Janna Neltner, Koping Chang, Stephen Yip, Osorio Lopes Abath Neto, Suash J Sharma, Richard Green, Maria A Gubbiotti, Leomar Y Ballester, Matthew Smith-Cohn, Cristina Vincentelli, William Yong, Christopher Mount, Michael Sun, Keith Ligon, Mariarita Santi, Emily Ling-Lin Pai, Gabrielle Yeaney, Sanda Alexandrescu, Igor Fernandes, Gerald Feliz Reis, Jacob Mandel, Omar H Butt, Sonika Dahiya, Sara Stone, Kyle Conway, MacLean P Nasrallah, Christine Fuller, Angus Toland, Rimas V Lukas, David Cachia, Erik J Uhlmann, Matthew McCord
Förderung
- NIH HHS
- U.S. Department of Health and Human Services
- National Institutes of Health
Zitieren
APA
Zhang, S., Singh, O., Dazelle, K., Quezado, M., Cimino, P. J., Abdullaev, Z., Wu, J., Lucas, C. H., Schreck, K. C., Holdhoff, M., Pytel, P., Goodwill, V., Macaulay, R., McDonald, W., Seidman, R., Wood, M., Bharani, K., Neltner, J., Richard, H., …, & McCord, M. (2026). High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag145
Vancouver
Zhang S, Singh O, Dazelle K, Quezado M, Cimino PJ, Abdullaev Z, et al. High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag145
BibTeX
@article{Zhang2026,
author = {Zhang, Shuodan and Singh, Omkar and Dazelle, Karen and Quezado, Martha and Cimino, Patrick J and Abdullaev, Zied and Wu, Jing and Lucas, Calixto-Hope and Schreck, Karisa C and Holdhoff, Matthias and Pytel, Peter and Goodwill, Vanessa and Macaulay, Rob and McDonald, William and Seidman, Roberta and Wood, Matthew and Bharani, Krishna and Neltner, Janna and Richard, Hope and Chang, Koping and Szymanski, Linda and Yip, Stephen and Mukherjee, Abir and Lopes Abath Neto, Osorio and Sharma, Suash J and Green, Richard and Brown, Daniel and Gubbiotti, Maria A and Ballester, Leomar Y and Eschbacher, Jennifer and Smith-Cohn, Matthew and Gokden, Murat and Vincentelli, Cristina and Yong, William and Lee, Julieann and Mount, Christopher and Fulmer, Joseph and Sun, Michael and Ligon, Keith and Santi, Mariarita and Pai, Emily Ling-Lin and Yeaney, Gabrielle and Alexandrescu, Sanda and Raghavan, Ravi and Fernandes, Igor and Reis, Gerald Feliz and Mandel, Jacob and Caccamo, Dario and Rao, Shilpa and Butt, Omar H and Dahiya, Sonika and Stone, Sara and Conway, Kyle and Nasrallah, MacLean P and Fuller, Christine and Toland, Angus and Lukas, Rimas V and Cachia, David and Uhlmann, Erik J and McCord, Matthew},
title = {High-grade astrocytoma with piloid features: A clinical and genomic analysis of prognostic factors using a large cohort},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag145}
}
EUVIMED